214 related articles for article (PubMed ID: 35174558)
21. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Sorbye H; Elvebakken H; Perren A; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Ladekarl M; Tabaksblat EM; Knappskog S
Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37410378
[TBL] [Abstract][Full Text] [Related]
22. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.
Viol F; Sipos B; Fahl M; Clauditz TS; Amin T; Kriegs M; Nieser M; Izbicki JR; Huber S; Lohse AW; Schrader J
Cell Oncol (Dordr); 2022 Dec; 45(6):1401-1419. PubMed ID: 36269546
[TBL] [Abstract][Full Text] [Related]
23. [Analysis of primary site and pathology on 903 patients with neuroendocrine neoplasms].
Qiu X; Liu M; Liu Q; Yang Z; Liu J; Meng F; Wang Z; Shi Y; Liu L; Zhang P; Luo J; Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):993-996. PubMed ID: 28900988
[TBL] [Abstract][Full Text] [Related]
24. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.
Boilève A; Faron M; Fodil-Cherif S; Bayle A; Lamartina L; Planchard D; Tselikas L; Kanaan C; Scoazec JY; Ducreux M; Italiano A; Baudin E; Hadoux J
Eur J Cancer; 2023 Jun; 186():122-132. PubMed ID: 37062210
[TBL] [Abstract][Full Text] [Related]
25. Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.
Prisciandaro M; Antista M; Raimondi A; Corti F; Morano F; Centonze G; Sabella G; Mangogna A; Randon G; Pagani F; Prinzi N; Niger M; Corallo S; Castiglioni di Caronno E; Massafra M; Bartolomeo MD; de Braud F; Milione M; Pusceddu S
Front Oncol; 2022; 12():780716. PubMed ID: 35186729
[TBL] [Abstract][Full Text] [Related]
26. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
27. [Clinicopathological characteristics and prognosis analysis of colorectal neuroendocrine neoplasms based on the data from domestic six medical centers].
Zhang Y; Peng X; Jin K; Wang W; Feng X; Zeng Y; Chen M; Yu X; Chen Y; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1235-1240. PubMed ID: 27928792
[TBL] [Abstract][Full Text] [Related]
28. The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan.
Yamamoto S; Sakakibara N; Hirano H; Morizane C; Honma Y; Hijioka S; Okusaka T; Higashi T; Kawai A
Sci Rep; 2022 Oct; 12(1):17601. PubMed ID: 36266484
[TBL] [Abstract][Full Text] [Related]
29. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
[TBL] [Abstract][Full Text] [Related]
32. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
[TBL] [Abstract][Full Text] [Related]
33. Correlation of World Health Organization 2010 Classification for Gastroenteropancreatic Neuroendocrine Neoplasms with the Prognosis of Ovarian Neuroendocrine Neoplasms: Kansai Clinical Oncology Group-Protocol Review Committee/Intergroup Study.
Kai K; Nasu K; Nishida H; Daa T; Shikama A; Shiozaki T; Kurakazu M; Yano M; Imamura Y; Tokunaga H; Tasaki K; Iida Y; Yamada Y; Morisawa H; Nakagawa S; Fujimoto E; Tsuruta T; Matsumoto H; Arakawa A; Nonaka M; Takano H; Ushiwaka T; Mori T; Ito K; Motohashi T; Teramoto N; Yamada T
Neuroendocrinology; 2021; 111(4):320-329. PubMed ID: 32097950
[TBL] [Abstract][Full Text] [Related]
34. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
35. Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis.
Bremer SCB; Bittner G; Elakad O; Dinter H; Gaedcke J; König AO; Amanzada A; Ellenrieder V; Freiherr von Hammerstein-Equord A; Ströbel P; Bohnenberger H
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740494
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological Findings and Treatment Outcomes of Patients with Primary Hepatobiliary Neuroendocrine Neoplasms: A Retrospective Single-institution Analysis.
Komiyama S; Okusaka T; Maruki Y; Ohba A; Nagashio Y; Kondo S; Hijioka S; Morizane C; Ueno H; Sukeda A; Mizui T; Takamoto T; Nara S; Ban D; Esaki M; Hiraoka N; Shimada K
Intern Med; 2024 Apr; 63(7):891-901. PubMed ID: 37612088
[TBL] [Abstract][Full Text] [Related]
37. [Well differentiated grade 3 gastroenteropancreatic neuroendocrine tumors:new insights into diagnosis and therapeutic strategy].
Fan ZY; Shi M; Yang J; Li YZ; Su P; Wang X; Zhan HX
Zhonghua Wai Ke Za Zhi; 2021 Aug; 59(8):704-710. PubMed ID: 34192864
[TBL] [Abstract][Full Text] [Related]
38. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
[TBL] [Abstract][Full Text] [Related]
39. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.
Pommergaard HC; Nielsen K; Sorbye H; Federspiel B; Tabaksblat EM; Vestermark LW; Janson ET; Hansen CP; Ladekarl M; Garresori H; Hjortland GO; Sundlöv A; Galleberg R; Knigge P; Kjaer A; Langer SW; Knigge U
J Neuroendocrinol; 2021 May; 33(5):e12967. PubMed ID: 33769624
[TBL] [Abstract][Full Text] [Related]
40. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]